share_log

AmeriCann Reports Q2 2022 Results

Benzinga Real-time News ·  Aug 16, 2022 15:40

A summary of operational highlights included the following:

  • AmeriCann's Operating Revenue from Building 1 increased over 36% from the quarter ended June 30, 2021, to the quarter ending June 30, 2022. Net Income increased by $261,689 to $162,734.
  • The Company achieved positive Adjusted EBITDA for the quarter of $438,890, an increase of 84% over the quarter ending June 2021. Adjusted Operating EBITDA margins for the quarter were 55.0%.
  • The manufacturing of cannabis-infused products, including the 1906 branded "Drops," Howl's Tincture, and Harpoon Extracts, has increased dramatically at the Massachusetts Cannabis Center. Sales of manufactured infused products are expected to be even stronger as continual increases in production and sales for 1906 "Drops" are realized.
  • The 1906 branded "Drops" has been the top-selling edible product in the Massachusetts market. Howl's Tincture was the top-selling brand in the tincture category.
  • For the first five months of 2022, the total cannabis sales revenue for the Massachusetts market was $708 million, which was 16% greater than the first five months of 2021. The annualized revenue estimate based on the first five months of 2022 is approximately $1.7 billion. Experts believe the market will exceed $1.8 billion annually.
    • The total Massachusetts market has sold $3.2 billion since the inception of the Commonwealth's regulated cannabis program.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment